Table 4. Decreased binding to site A and B mutants by human plasma after vaccination.
| Mutant | Vaccinated 2006–07 (18 subjects) | Vaccinated 2008–09 (11 subjects) | ||
| Number1 | Percent | Number | Percent | |
| Site B | ||||
| HL156-157KS | 6 | 33 | 3 | 27 |
| KFK158-160GST | 11 | 61 | 7 | 64 |
| NDQ189-192QEQT | 5 | 28 | 2 | 18 |
| A196V | 1 | 0 | 0 | 0 |
| Total subjects binding site B | 12 | 66 | 7 | 64 |
| Site A | ||||
| NNES121-124ITEG | 4 | 22 | 2 | 18 |
| N126T | 3 | 17 | 2 | 18 |
| N133D | 3 | 17 | 1 | 9 |
| TSSS133-138GSNA | 2 | 11 | 0 | 0 |
| K140I | 6 | 33 | 0 | 0 |
| RSNNS142-146GPGSG | 3 | 17 | 2 | 18 |
| Total subjects binding site A | 7 | 39 | 2 | 18 |
| Total A, B or both | 13 | 72 | 8 | 73 |
| Not A or B | 5 | 28 | 3 | 27 |
1
Number of subjects who showed decreased avidity (Kd increased by ≥30%) to the mutant HA.